IL33

Across TCGA pan-cancer cohorts, IL33 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IL33’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IL33 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IL33 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where IL33 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IL33 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−1.864	<.001	12	view →
LUAD	Female	III,IV	−2.113	<.001	9	view →
LSCC	Male	All	−1.827	<.001	8	view →
CCRCC	All	III,IV	−0.313	.003	6	view →
COAD	All	All	−0.220	.012	3	view →
OV	All	All	−1.815	.001	2	view →
PDAC	All	IV	−2.215	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IL33–HNSC

Open the HNSC breakdown →